Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars

Executive Summary

'This is important for our own pharmacovigilance,' US FDA commissioner says. 'We still have an open question on whether or not we’re going to apply a suffix or change also the branded company’s name as well.'


Related Content

US FDA's Biosimilars Chief Leah Christl Plans Departure
With Biosimilar Statistical Guidance Withdrawn, Expect Sponsor-Specific Advice, FDA's Christl Says
Industry May Like FDA's Biosimilar Guidance Withdrawal, But Not The New Information Vacuum
USP Backs Down From Biologic Monograph Naming Plan Amid US FDA Objections
First Three Novel Biologic Suffixes Came Courtesy Of US FDA, Not Sponsors
Biologics Naming: US FDA Ponders How To Put New System In Place, While WHO Puts Hold On Pilot Study
FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
US FDA Likely Not 'Significant', Could Be Mostly Spared From Trump's Regulation-Slashing Order
Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
From Random To Meaningful: The Evolution Of Zarxio’s Suffix


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts